Holen Sie sich die Stockscreener-App
7.17
1.78%
-0.13
Handel nachbörslich:
7.17
Schlusskurs vom Vortag:
$7.30
Offen:
$7.28
24-Stunden-Volumen:
722.07K
Relative Volume:
0.56
Marktkapitalisierung:
$440.20M
Einnahmen:
$91.06M
Nettoeinkommen (Verlust:
$-503.14M
KGV:
-0.8546
EPS:
-8.39
Netto-Cashflow:
$-424.74M
1W Leistung:
-7.72%
1M Leistung:
+4.52%
6M Leistung:
+20.71%
1J Leistung:
-48.57%
1-Tages-Spanne:
$7.135
$7.36
1-Wochen-Bereich:
$7.135
$7.82
52-Wochen-Spanne:
$4.62
$14.31
Sage Therapeutics Inc Stock (SAGE) Company Profile
Firmenname
Sage Therapeutics Inc
Sektor
Branche
Telefon
617-299-8380
Adresse
55 CAMBRIDGE PARKWAY, CAMBRIDGE, MA
Vergleichen Sie SAGE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SAGE
Sage Therapeutics Inc
|
7.17 | 440.20M | 91.06M | -503.14M | -424.74M | -8.39 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.19 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
603.58 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
656.65 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
273.55 | 32.98B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
254.16 | 26.92B | 3.81B | -644.79M | -669.77M | -6.24 |
Sage Therapeutics Inc Stock (SAGE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-11 | Fortgesetzt | BofA Securities | Underperform |
| 2024-11-21 | Hochstufung | RBC Capital Mkts | Underperform → Sector Perform |
| 2024-10-10 | Fortgesetzt | Raymond James | Mkt Perform |
| 2024-10-04 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-07-30 | Herabstufung | TD Cowen | Buy → Hold |
| 2024-07-25 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-05-29 | Eingeleitet | Citigroup | Sell |
| 2024-05-29 | Eingeleitet | Robert W. Baird | Neutral |
| 2024-04-17 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2023-12-12 | Eingeleitet | Deutsche Bank | Hold |
| 2023-08-08 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2023-08-08 | Herabstufung | Goldman | Buy → Neutral |
| 2023-08-08 | Herabstufung | Needham | Buy → Hold |
| 2023-08-07 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-08-07 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2023-08-07 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-08-07 | Herabstufung | Stifel | Buy → Hold |
| 2023-08-07 | Herabstufung | Wedbush | Outperform → Neutral |
| 2023-07-27 | Eingeleitet | Scotiabank | Sector Outperform |
| 2023-03-13 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-01-03 | Herabstufung | Guggenheim | Buy → Neutral |
| 2022-11-01 | Eingeleitet | Loop Capital | Hold |
| 2022-03-31 | Eingeleitet | Berenberg | Hold |
| 2021-11-02 | Hochstufung | Guggenheim | Neutral → Buy |
| 2021-10-19 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2021-10-07 | Herabstufung | Jefferies | Buy → Hold |
| 2021-09-23 | Eingeleitet | Needham | Buy |
| 2021-06-16 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-04-07 | Eingeleitet | Piper Sandler | Overweight |
| 2021-02-26 | Herabstufung | Mizuho | Buy → Neutral |
| 2021-02-25 | Bestätigt | H.C. Wainwright | Neutral |
| 2021-02-02 | Fortgesetzt | Raymond James | Mkt Perform |
| 2021-01-22 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2021-01-04 | Hochstufung | Guggenheim | Neutral → Buy |
| 2021-01-04 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-12-04 | Hochstufung | Mizuho | Neutral → Buy |
| 2020-12-01 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2020-11-16 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-11-06 | Bestätigt | H.C. Wainwright | Neutral |
| 2020-09-11 | Hochstufung | Wedbush | Neutral → Outperform |
| 2020-08-10 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2020-05-08 | Herabstufung | Wedbush | Outperform → Neutral |
| 2020-04-08 | Herabstufung | Guggenheim | Buy → Neutral |
| 2020-03-18 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-03-06 | Eingeleitet | Citigroup | Buy |
| 2020-02-28 | Bestätigt | H.C. Wainwright | Neutral |
| 2020-02-06 | Eingeleitet | Mizuho | Neutral |
| 2019-12-06 | Bestätigt | RBC Capital Mkts | Outperform |
| 2019-12-05 | Bestätigt | Guggenheim | Buy |
| 2019-12-05 | Herabstufung | SunTrust | Buy → Hold |
| 2019-10-30 | Eingeleitet | H.C. Wainwright | Neutral |
| 2019-05-23 | Eingeleitet | Wedbush | Outperform |
| 2019-04-25 | Eingeleitet | Jefferies | Buy |
| 2018-12-14 | Eingeleitet | Wolfe Research | Outperform |
| 2018-10-11 | Eingeleitet | Oppenheimer | Outperform |
Alle ansehen
Sage Therapeutics Inc Aktie (SAGE) Neueste Nachrichten
Invesco Ltd. Purchases 4,629 Shares of Sage Therapeutics, Inc. (NASDAQ:SAGE) - Defense World
Press Release Distribution & PR Platform - ACCESS Newswire
What is HC Wainwright’s Forecast for SAGE Q1 Earnings? - Defense World
Sage Therapeutics' Q1 Earnings Miss Mark, Revenue Rise Y/Y - MSN
Sage Therapeutics, Inc. (NASDAQ:SAGE) Q1 2025 Earnings Call Transcript - Insider Monkey
Sage Therapeutics’ Earnings Call Highlights Growth and Uncertainty - TipRanks
Balance Sheet Breakdown: Sage Therapeutics Inc (SAGE)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - DWinneX
Sage Therapeutics Inc (SAGE) Q1 2025 Earnings Call Highlights: Strong Demand for ZURZUVAE and ... - Yahoo Finance
SAGE Reports Q1 Revenue Below Estimates, Highlights ZURZUVAE Gro - GuruFocus
Sage Therapeutics Inc (SAGE) Q1 2025 Earnings Call Highlights: S - GuruFocus
Sage Therapeutics Reports Strong Q1 2025 Performance - TipRanks
Sage Therapeutics outlines Q1 2025 growth in ZURZUVAE prescriptions and pipeline progress - MSN
Sage Therapeutics Q1 2025 Earnings: Revenue at $13.8M Misses Est - GuruFocus
Sage Therapeutics, Inc. 2025 Q1ResultsEarnings Call Presentation (NASDAQ:SAGE) - Seeking Alpha
Earnings call transcript: Sage Therapeutics misses Q1 2025 EPS forecast By Investing.com - Investing.com Nigeria
Earnings call transcript: Sage Therapeutics misses Q1 2025 EPS forecast - Investing.com
Sage Therapeutics Announces First Quarter 2025 Financial Results - GuruFocus
Sage Therapeutics, Inc. (SAGE) Reports Q1 Loss, Misses Revenue Estimates - Nasdaq
Sage Therapeutics Announces First Quarter 2025 Financial Results and Highlights Pipeline and Business Updates - BioSpace
SAGE THERAPEUTICS Earnings Results: $SAGE Reports Quarterly Earnings - Nasdaq
What to Expect from Sage Therapeutics's Earnings - Benzinga
Get in on Sage Therapeutics Inc’s (SAGE) buy-in window today! - Sete News
Sage Therapeutics Inc [SAGE] Insider Activity: An Update for Investors - knoxdaily.com
Sage Therapeutics’ (SAGE) “Hold” Rating Reiterated at Needham & Company LLC - Defense World
Expert Outlook: Sage Therapeutics Through The Eyes Of 4 Analysts - Benzinga
Geode Capital Management LLC Increases Stock Holdings in Sage Therapeutics, Inc. (NASDAQ:SAGE) - Defense World
Russell Investments Group Ltd. Lowers Stock Holdings in Sage Therapeutics, Inc. (NASDAQ:SAGE) - Defense World
Kuehn Law Encourages Investors of Sage Therapeutics, Inc. to Contact Law Firm - PR Newswire
Sage Therapeutics, Inc. (SAGE) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release - Yahoo Finance
Sage Therapeutics (SAGE) Projected to Post Quarterly Earnings on Tuesday - Defense World
Sage Therapeutics, Inc. (NASDAQ:SAGE) Given Consensus Recommendation of “Hold” by Analysts - Defense World
Sage Therapeutics, Inc. (SAGE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - markets.businessinsider.com
Wedbush Research Analysts Raise Earnings Estimates for SAGE - American Banking and Market News
Lobbying Update: $50,000 of SAGE THERAPEUTICS lobbying was just disclosed - Nasdaq
Q1 EPS Estimates for Sage Therapeutics Increased by Wedbush - Defense World
Q1 Earnings Forecast for SAGE Issued By Wedbush - Defense World
Bronstein, Gewirtz & Grossman, LLC Is Investigating Sage Therapeutics, Inc. (SAGE) And Encourages Investors to Connect - markets.businessinsider.com
Bronstein, Gewirtz & Grossman, LLC Is Investigating Sage Therapeutics, Inc. (SAGE) And Encourages Stockholders to Connect - markets.businessinsider.com
Sage Therapeutics to Report First Quarter 2025 Financial Results on Tuesday, April 29, 2025 - BioSpace
Sage Therapeutics to Report First Quarter 2025 Financial Results on Tuesday, April 29, 2025 | SAGE Stock News - GuruFocus
Corebridge Financial Inc. Sells 2,050 Shares of Sage Therapeutics, Inc. (NASDAQ:SAGE) - Defense World
Sage Therapeutics, Inc. (NASDAQ:SAGE) Shares Sold by Vanguard Group Inc. - Defense World
Finanzdaten der Sage Therapeutics Inc-Aktie (SAGE)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.39%
3.66%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):